Atherosclerosis and Lipoproteins |
From MRC Clinical Trials Unit (A.R.B.), London, UK; the Department of Public Health Sciences (F.G.R.F.), University of Edinburgh, UK; MRC Biostatistics Unit (S.G.T.), Cambridge, UK; and the University Hospitals of Coventry and Warwickshire (J.T.P.), Coventry, UK.
Correspondence to Mr A.R. Brady, MRC Clinical Trials Unit, 222 Euston Rd, London NW1 2DA, UK. E-mail tbrady{at}ctu.mrc.ac.uk
| Abstract |
|---|
|
|
|---|
Key Words: aneurysm aorta survival
| Introduction |
|---|
|
|
|---|
5% in prospective
studies.1 2 There
are numerous reports of mortality related to elective surgery, with a
recent overview identifying 72 publications representing
37 654 patients from 1985 to
1996.2 In comparison, far
fewer studies have investigated late survival after AAA
repair. Studies of late survival are often complicated by the unavailability of comprehensive follow-up data. Nevertheless, several recent studies have indicated that even after patients experience a full recovery from surgical repair, their survival appears to be worse than that in an age- and sex-matched population.3 4 5 6 The population-based study from the Mayo clinic reported a 5-year survival of only 60% after repair of AAAs >5 cm in diameter compared with the expected survival of 77% of other age- and sex-matched community residents (P<0.01).3 The majority of late deaths were from cardiovascular causes. The difference between the survival of patients undergoing surgery for small aneurysms (<5 cm in diameter) and other community residents was less marked and only of borderline significance (P=0.05).3 In a recent French study, the 5-year survival after aneurysm repair was reported as 72% compared with 90% in the age- and sex-matched population.5 Similarly, a study in Berkshire, England, showed that the 5-year survival of patients undergoing surveillance with AAAs <4 cm and 4 to 5.5 cm in diameter was 62% and 45%, respectively, compared with 80% in an age- and sex-matched population.7 Again, the majority of late deaths were from cardiovascular causes.7 Only an earlier American study, with a policy of selective coronary artery revascularization, and a recent Australian study have shown 5-year survival for AAA patients to be equivalent to age- and sex-matched populations.8 9 In the Australian study, however, women with AAAs still experienced worse 5-year survival rates than did the age-matched controls.9
These studies suggest that the presence of small AAAs may be a marker for risk of death from cardiovascular diseases in general rather than specifically from aneurysm rupture. We can investigate this hypothesis further by looking for a dose-response relationship in patients with AAAs according to aneurysm diameter. We have used the prospective data from the UK Small Aneurysm Trial and Study to test the hypothesis that for AAA patients, the risk of nonaneurysm cardiovascular mortality increased with aneurysm diameter before rupture and repair and after surgery.
| Methods |
|---|
|
|
|---|
The relationship between aneurysm diameter and survival was considered in 2 time periods: (1) the surveillance period before surgical intervention or aneurysm rupture and (2) the long-term postoperative period after AAA surgery. For the purposes of analysis, the surveillance period extended from initial assessment until aneurysm repair/rupture or end of active follow-up. The postoperative period extended from surgery until notification of deaths from the Office of National Statistics was discontinued (end of November 1998 for study patients and end of June 1999 for trial patients).
Univariate estimates of survival were calculated by using the Kaplan-Meier method according to tertiles of AAA diameter. Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) for the effect of baseline aneurysm diameter on survival. All Cox models included adjustments for "design" effects: source of referral (eg, general practitioner, hospital clinic, or other), region (Scotland, London, Leicester, Manchester, or Bath), hospital type (teaching or district general), and study group (trial group, unfit group, small aneurysm group, group scheduled for surgery, and group who refused trial). Further adjustments were made for the following baseline measurements: age, sex, ankle/brachial pressure index, angina (from Rose questionnaire),11 evidence of ischemic heart disease on baseline ECG, smoking status, total serum cholesterol, diabetes, systolic and diastolic blood pressure, body mass index, white cell count, blood creatinine, and forced expiratory volume in 1 second. Aneurysm diameter, white cell count, and creatinine were logarithmically transformed because of right skew in their original distributions. Nonlinearity in the association between aneurysm diameter and survival was investigated by comparing a first-degree fractional polynomial with a linear model.12 Nonproportional hazards for aneurysm diameter were investigated by a test for nonzero slope in a regression of the scaled Schoenfeld residuals on time.13 For analysis of cardiovascular mortality, patients were censored at their times of death from noncardiovascular causes.
| Results |
|---|
|
|
|---|
|
Surveillance Period Before Surgery or
Rupture
Patients (n=2305) were followed up for a mean of 1.7
years in the surveillance period before aneurysm repair or
rupture. There were 259 deaths; 175 (68%) were from
cardiovascular causes
(Table 2
). The 40 deaths from aneurysm rupture were
excluded from subsequent analyses. Median aneurysm
diameter at baseline was 4.4 cm (range 3.0 to 9.7 cm). There was a
clear association between aneurysm diameter and survival
(Figure 1
). For all-cause mortality, the HR for a 1-SD
increase in logarithmic aneurysm diameter (corresponding to
18% of original diameter, or
0.8 cm) was 1.32
(Table 3
). The HR was higher for patients enrolled in the
trial (HR 2.25, 95% CI 1.57 to 3.23) than for those in the study (HR
1.12, 95% CI 0.92 to 1.37;
P<0.001 by test of
interaction). This interaction appeared to be caused by unfit study
patients, for whom little evidence of an association between
aneurysm diameter and survival could be found (HR 0.96, 95% CI
0.75 to 1.23). The HR in the remaining study patients was 1.70 (95% CI
1.12 to 2.57). There was little evidence of nonlinearity in the
relationship between logarithmic aneurysm diameter and survival
(P=0.12) or nonproportional
hazards over time
(P=0.18).
|
|
|
Aneurysm diameter was weakly associated with sex
(median was 4.4 cm in men compared with 4.2 cm in women) but was not
correlated with other baseline measurements. Consequently, adjustment
for baseline measures in the Cox model made little difference to the
estimated effect for aneurysm diameter (HR 1.31,
Table 3
).
The relative hazard of cardiovascular death
per SD increase in logarithmic aneurysm diameter was 1.35 when
unadjusted and 1.34 when adjusted for all baseline measures
(Table 3
).
Postoperative Period
Aneurysm repair was performed in 1139 patients.
Mean follow-up time for mortality after repair was 3.6 years. There
were 325 deaths; 221 (68%) were from cardiovascular
causes
(Table 2
). Median aneurysm diameter immediately
before surgery was 5.1 cm (range 3.2 to 9.2 cm). Five-year survival was
69% (95% CI 66% to 72%). The association between aneurysm
diameter and survival
(Figure 2
) corresponds to a marginally significant HR of 1.12
for a 1 SD increase in logarithmic aneurysm diameter
(Table 3
). This was similar in trial and study patients
(P=0.58 by test of
interaction). There was no evidence of nonlinearity in the relationship
between logarithmic aneurysm diameter and survival
(P=1.00) or nonproportional
hazards over time
(P=0.61).
|
Aneurysm diameter at surgery was weakly associated
with sex (median 5.1 cm in men and 4.9 cm in women) and was correlated
with age at surgery (by Spearman rank correlation,
=0.11) and body
mass index (
=0.13). Adjustment for baseline measures in the Cox
model increased the estimated effect for aneurysm diameter (HR
1.26,
Table 3
). After exclusion of 84 patients who died within 30
days of AAA repair, the adjusted HR was 1.20 (95% CI 0.99 to 1.46).
Therefore, the effect of aneurysm diameter on mortality in the
postoperative period was not merely a result of early surgical
deaths.
The association between aneurysm diameter and
cardiovascular mortality was similar to that for
all-cause mortality. The relative hazard of
cardiovascular death per SD increase in logarithmic
aneurysm diameter was 1.13 when unadjusted and 1.31 when
adjusted for all baseline measures
(Table 3
).
| Discussion |
|---|
|
|
|---|
There is considerable literature on predictors of survival for patients with AAA. Several previous studies have identified renal function as having prognostic significance in these patients.6 8 14 15 There has been much discussion about whether myocardial revascularization should precede AAA repair and whether coronary artery disease predicts early and late survival in AAA patients,4 6 8 14 16 17 and the data are not consistent. Very recently, we have reported that the ankle/brachial pressure index is a powerful predictor of survival for AAA patients.18 The ankle/brachial pressure index has been shown to indicate the extent of generalized atherosclerosis in population studies.19 Patients presenting with AAA and having an ankle/brachial pressure index of <0.9 should be targeted for modification of cardiovascular risk factors, including lifestyle changes and cholesterol reduction.
Certainly, the proposition that aneurysms are caused by atherosclerosis20 might explain the high proportion (68%) of deaths from cardiovascular causes. If aneurysms are caused by atherosclerosis, one might anticipate that increasing aneurysm diameter would be an index of atherosclerotic burden. However, if anything, adjustment for atherosclerotic risk factors (smoking, cholesterol, diabetes, and blood pressure) and other known cardiovascular indices, including ECG findings and ankle/brachial pressure index, strengthens the association between aneurysm diameter and cardiovascular mortality. This suggests that other, nonatherosclerotic mechanisms may underlie the association between aneurysm diameter and survival. For instance, circulating interleukin-6 (IL-6) has recently been confirmed as a cardiovascular risk factor.21 Aortic aneurysms are an important source of this cytokine, and the secretion of IL-6 increases with aortic diameter.22 The aneurysm wall could be a source of IL-6 and other circulating factors that influence myocardial function, inflammation, or thrombosis.
The principal limitation of the present study is the ascertainment of cause of death, because a postmortem examination was performed for only 30% of the deaths. Therefore, the deaths due to AAA rupture may have been underestimated: the risk of rupture increases with AAA diameter.23 However, the association between AAA diameter and cardiovascular mortality before surgery was strongest for trial patients, in whom the risk of cardiovascular death increased >2-fold for each 0.8-cm increase in aneurysm diameter. These patients were followed very closely, making unreported ruptures unlikely. Therefore, we do not think that unreported ruptures explain the association between AAA diameter and mortality. The strengths of the present study include its size and high quality of prospective data, obtained by dedicated trial coordinators. The present study also benefited from the British system of tracing and reporting deaths, which avoids patients being lost to follow-up.
The association between AAA diameter and survival, which we report, may have more importance for elucidation of the mechanism underlying the association than for patient management, particularly because the HRs in the surveillance and postoperative period were very similar. Current evidence-based guidelines suggest that aneurysms >5.5 cm in diameter should be repaired, to minimize the risk of aneurysm rupture. Because of the clear association between smoking and aneurysm rupture,23 all patients should be counseled to stop smoking. Many of the patients in the present study were continuing smokers. In vascular surgical clinics, measurement of ankle/brachial pressure index may provide a more useful guide to management of cardiovascular risk factors than aortic diameter, at least until we understand the mechanisms underlying the association between aneurysm diameter and survival.
| Acknowledgments |
|---|
Received January 17, 2001; accepted January 17, 2001.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. S. Al-Barjas, R. Ariens, P. Grant, and J. A. Scott Raised Plasma Fibrinogen Concentration in Patients With Abdominal Aortic Aneurysm Angiology, October 1, 2006; 57(5): 607 - 614. [Abstract] [PDF] |
||||
![]() |
T. Tsuruda, J. Kato, K. Hatakeyama, A. Yamashita, K. Nakamura, T. Imamura, K. Kitamura, T. Onitsuka, Y. Asada, and T. Eto Adrenomedullin in mast cells of abdominal aortic aneurysm Cardiovasc Res, April 1, 2006; 70(1): 158 - 164. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. T. Hirsch, Z. J. Haskal, N. R. Hertzer, C. W. Bakal, M. A. Creager, J. L. Halperin, L. F. Hiratzka, W. R.C. Murphy, J. W. Olin, J. B. Puschett, et al. ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary A Collaborative Report From the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1239 - 1312. [Full Text] [PDF] |
||||
![]() |
P. Norman, M. Le, C. Pearce, and K. Jamrozik Infrarenal Aortic Diameter Predicts All-Cause Mortality Arterioscler. Thromb. Vasc. Biol., July 1, 2004; 24(7): 1278 - 1282. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Pasternak, M. H. Criqui, E. J. Benjamin, F. G. R. Fowkes, E. M. Isselbacher, P. A. McCullough, P. A. Wolf, and Z.-J. Zheng Atherosclerotic Vascular Disease Conference: Writing Group I: Epidemiology Circulation, June 1, 2004; 109(21): 2605 - 2612. [Full Text] [PDF] |
||||
![]() |
M. A. Creager, D. W. Jones, J. D. Easton, J. L. Halperin, A. T. Hirsch, A. H. Matsumoto, P. T. O'Gara, R. D. Safian, G. L. Schwartz, and J. A. Spittell Atherosclerotic Vascular Disease Conference: Writing Group V: Medical Decision Making and Therapy Circulation, June 1, 2004; 109(21): 2634 - 2642. [Full Text] [PDF] |
||||
![]() |
The United Kingdom Small Aneurysm Trial Participan Long-Term Outcomes of Immediate Repair Compared with Surveillance of Small Abdominal Aortic Aneurysms N. Engl. J. Med., May 9, 2002; 346(19): 1445 - 1452. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |